Probucol (Lorelco)

02/01/1992 - "Thus, probucol was effective in preventing atherosclerosis in long-term studies at both early and late stages."
02/01/1992 - "In the second study (study B), administration of probucol was commenced with 8-month-old WHHL rabbits to investigate whether the drug was effective for limiting atherosclerosis in rabbits in which plaques had already developed. "
01/01/2000 - "Protective effects of probucol in two animal models of atherosclerosis."
01/01/2023 - "In this study, we devised a highly sensitive H2O2-scavenging nano-bionic system loaded with probucol (RPP-PU), to treat atherosclerosis more effectively. "
01/01/2018 - "This might explain why probucol failed to protect against atherosclerosis in various clinical trials. "

11/01/2018 - "We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice. "
05/01/2002 - "Probucol is also used for hypercholesterolemia and recently is known that it prevent the restenosis of the coronary artery after PTCA. "
07/01/1999 - "Effect of probucol on hypercholesterolemia in renal transplant patients."
07/01/1999 - "They also suggest that the reduction of hypercholesterolemia after the change in diet or treatment with probucol suppressed glomerular injury by suppressing the glomerular MCP-1 expression. "
01/01/1998 - "Evaluation of effectiveness of hypolipidemic action of probucol in doses 500 and 1000 mg/day and comparison of probucol blood concentrations on the treatment month 3 and 6. Probucol (Akrikhin, Russia) was given to 41 patients with primary hypercholesterolemia in a dose 500 mg/day. "

11/01/2003 - "Probucol has been reported to completely prevent DOX-induced cardiomyopathy. "
06/01/2000 - "An increase in oxidative stress, GSHPx inactivation and MnSOD downregulation during ADR cardiomyopathy were prevented by probucol treatment."
06/01/2000 - "Probucol has been reported to completely prevent ADR cardiomyopathy without interfering with its antitumor effects. "
02/01/2001 - "Apoptosis in adriamycin cardiomyopathy and its modulation by probucol."
06/01/1999 - "Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy."

01/01/2018 - "Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone."
03/17/2023 - "Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI. "
05/01/2006 - "One hundred and twelve patients with coronary heart disease were randomly divided into XZKC-treated group and probucol-treated group, 56 in each. "
05/01/2006 - "CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol."
10/30/1980 - "However, no unexpected overall excess of mortality was observed with long-term probucol treatment; there was no increase in morbidity, nor in sudden deaths or deaths from coronary disease. "

09/30/1994 - "The study group consisted of 48 males and 56 females with hyperlipidemia taking part in the open prerandomization phase of the Probucol Quantitative Regression Swedish Trial (PQRST). "
11/01/2006 - "Probucol supplement under hyperlipidemia status preserves EDR and not endothelium-independent relaxation."
10/01/1997 - "Hence, probucol administration after vascular reconstruction with vein grafts in patients with hyperlipidemia may be beneficial."
05/01/1997 - "Probucol effectively inhibited the development of glycemia, hyperlipidemia, and intensification of autooxidation in the vascular wall. "
12/01/1994 - "[Probucol treatment of hyperlipidemia]."